Among the preterm infants who develop neonatal respiratory distress syndrome some require prolonged ventilatory support for the chronic lung disease of prematurity or bronchopulmonary dysplasia.12 This is an increasingly common cause of chronic lung disease in infants, affecting about 20% of preterm survivors, with up to 7000 new cases a year in the United States. 2 After the initial phase of damage due to surfactant deficiency, barotrauma, and oxygen toxicity, local inflammation is important in the progression to chronic lung disease.' Corticosteroids have been used to limit inflammatory damage and are usually given after two to four weeks. The cytokine tumour necrosis factor a is a potent mediator ofpulmonary inflammation, in addition to its better known systemic effects.45 It has been postulated that local pulmonary production by alveolar macrophages contributes to the adult respiratory distress syndrome,'9 but its production in the respiratory distress syndrome of infancy has not been documented. We determined tumour necrosis factor a concentrations in pulmonary secretions in infants with the respiratory distress syndrome and the effect of treatment with dexamethasone on the concentrations of tumour necrosis factor a in airways secretions.
Methods

PATIENTS STUDIED
Twenty eight preterm infants (24-31 weeks' gestation, birth weight 570-2200 g) were studied. All required assisted ventilation for the respiratory distress syndrome (for 4-73 days). Two infants died during the study, one from early progressive lung damage and the other after intraventricular haemorrhage. Eleven of the infants had an uncomplicated course, being weaned from the ventilator and on to room air within 28 days. Six developed mild chronic lung disease, requiring supplemental oxygen for up to 60 days, and a further nine developed more severe bronchopulmonary dysplasia, requiring oxygen for 70-160 days.
Six infants were treated with dexamethasone, five at the age of 28 days because they needed prolonged ventilation. All five improved and four were extubated within five days. The sixth was treated at 14 days for severe lung disease of early onset and did not improve. factor a in lavage fluid for each infant in a given age range (from 1 to 3 results) were averaged (figure 1). Comparison between these groups at different ages was made with the KolmogorovSmirnov two group test, as were any additional comparisons using these groups. The MannWhitney U test was used for comparison be-.
EXCLUSIONS
tween the groups with the uncomplicated respiratory distress syndrome and those needing prolonged oxygen treatment, a mean tumour necrosis factor concentration for all measurements after day 3 having been derived for each infant. The Mann-Whitney U test was also used to compare tumour necrosis factor [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] concentrations before and after treatment in the infants given dexamethasone (fig 2) , and concentrations in infants with and without ary infection or colonisation of secretions.
days at Psisfactor
Results TUMOUR NECROSIS FACTOR CX AND AGE Tumour necrosis factor a was detectable in % saline airways secretions during the first 3 days of life I into the in 11 of 20 infants, but levels were generally econnec-low, on average <55 pg/ml (fig 1) . The levels catheter were significantly higher in the secretions samp of the pled on days 4-7 (p < 0 05), days [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] ied. The (p < 0-001) and days [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] After the primary insult in the first days of life there is an inflammatory response,' more pronounced in those who develop bronchopulmonary dysplasia, which is associated with an increased ratio of proteases to protease inhibitors." 12High concentrations offibronectin" may contribute to monocyte chemotaxis'4 and possibly also to fibrosis.'3 Alveolar macrophages from preterm infants produce free radicals, the concentrations of which are increased in infants with bronchopulmonary dysplasia and decreased in those receiving glucocorticoid treatment.'5 Alveolar macrophages in vitro produce large amounts of tumour necrosis factor a on being stimulated'6 and in animals and man pharmacological doses can directly cause lung damage.9'7'8 High concentrations of tumour necrosis factor a occur in bronchoalveolar secretions of adults with the adult respiratory distress syndrome67 and may be a mediator of injury in this condition,89 which has many similarities to the neonatal respiratory distress syndrome.
Tumour necrosis factor a may potentially induce lung damage by polymorph chemotaxis, endothelial localisation, and stimulation of the respiratory burst,419 20 and neutropenia has been shown to protect animals against pulmonary damage induced by tumour necrosis factor a.21 It may also stimulate production of other mediators and contribute to pulmonary fibrosis.452324 Of potential relevance in the neonatal respiratory distress syndrome is the finding, in vitro, that tumour necrosis factor a inhibits expression of pulmonary surfactant proteins SP-A and SP-B,25 which appear necessary for normal surfactant function. 26 The finding of local production of tumour necrosis factor a by the age of 4 days in the neonatal respiratory distress syndrome suggests several therapeutic possibilities. Corticosteroids, which decrease both synthesis and release oftumour necrosis factor c,4 5 
